Knowledge about the molecular mechanisms involved in the pathogenesis of tumoral progression in mycosis fungoides (MF) is still scarce. Because the 9p21 locus seems to be a good target for a detailed study in MF, this prompted us to compare the mechanisms of inactivation of the p16
M
ycosis fungoides (MF) is an indolent subtype of cutaneous T-cell lymphoma that slowly evolves through patch, plaque, and tumor stages before the lymph nodes and visceral organs become involved. The evolution from a disease restricted to the skin towards a widespread disseminated disease may take years or even decades. The timing of this aggressive transformation varies from case to case, thus whereas some patients may show an aggressive course from the beginning, in others the disease follows a protracted course, which suggests that there is some variability in the biologic characteristics of these neoplasms that decides the moment at which the aggressive transformation takes place (Diamandidou et al, 1996) .
The 9p21 region encodes the growth suppressor genes p16
INK4a , p15 INK4b , and p14 ARF . Alterations in this region are one of the most frequent findings in human cancer (Sherr, 1996) . It has been shown that p16
INK4a and p14 ARF , the two alternative products of the 9p21 region, play key roles in the maintenance of the Rb and p53 tumor suppressor pathways, respectively (Ching et al, 1998) , whereas p15 INK4b is a mediator of extracellular growth inhibition signals (Hannon and Beach, 1994) .
INK4 proteins (p16 INK4a and p15 INK4b ) specifically bind to and inhibit the cyclin D-dependent kinases (CDKs), CDK4 and CDK6, thus preventing pRb phosphorylation and exit from the G1 phase (Serrano, 1997) . In contrast with this, p14 ARF does not bind to CDKs but interacts and sequesters Mdm2 (Kamijo et al, 1998; Lohrum et al, 2000; Zhang et al, 1998) , a protein that has the capacity of promoting p53 degradation and also functionally inactivating Rb, leading to cell cycle arrest (Carnero et al, 2000; Pomeranntz et al, 1998; Weber et al, 1999) .
Genetic and epigenetic alterations of the INK4/ARF locus on 9p21 are one of the most frequent molecular alterations observed in human tumorigenesis (Cairns et al, 1995; Kamb et al, 1994) . Different mechanisms of inactivation of these genes have been described in different types of human cancer. Homozygous deletions (HD), methylation, and mutation of the INK4/ARF locus have been reported in lymphoid malignancies (Drexler, 1998; Gombart et al, 1995; Herman et al, 1996b; Koduru et al, 1995; Ogawa et al, 1995; Quelle et al, 1997; Siebert et al, 1995) , such as lymphoblastic lymphoma/acute lymphoblastic leukemia (Gardie et al, 1998; Okuda et al, 1995) , and in B-cell lymphomas (Baur et al, 1999; Fernandez-Piqueras et al, 1997; Herman et al, 1997; Klangby et al, 1998; Martínez-Delgado et al, 1998; Ng et al, 1997) , where it has been shown to be involved in the transformation of lowgrade to high-grade tumors (Elenitoba-Johnson et al, 1998; Pinyol et al, 1998; Villuendas et al, 1998) .
Methylation of the different genes present in 9p21 seems to be a random phenomenon, which may affect only one of the genes or combinations of them, in a pattern that has been linked to specific types of neoplasms. Thus, concomitant hypermethylation of p16 INK4a /p15 INK4b genes, which is unusual in other malignancies (such as myeloblastic leukemia, lymphoblastic leukemia, and glioma) (Aggerholm et al, 1999; Cameron et al, 1999; Herman et al, 1996b) , has often recently been detected in multiple myeloma (Ng et al, 1999) . The p14 ARF promoter demonstrates selective epigenetic silencing in a subset of colorectal tumors, with a hypermethylated promoter (p14 ARF ) between two unmethylated promoters (p16 INK4a and p15 INK4b ) that in contrast are frequently methylated in other tumor types (Esteller et al, 2000) . Recent studies (Baur et al, 1999) have observed the absence of p14 ARF gene mutations or methylation in all lymphomas analyzed, which suggests that p14 ARF inactivation is not implicated in human lymphomagenesis or could be dependent on additional and varied mechanisms.
The molecular mechanisms underlying the progression of MF into tumoral stage, a phenomenon usually associated with large cell transformation and aggressive behavior, are not well known. Several articles have shown a low frequency of genetic alterations associated with p53, lyt10, c-myc, bcl-1, and bcl-2 genes in patients with MF (de Misa et al, 1995; Garatti et al, 1995) . Recently, Scarisbrick et al (2000) found loss of heterozygosity (LOH) on 10q and microsatellite instability in advanced cutaneous stages of MF, suggesting that a tumor suppressor gene or genes in this region may be associated with disease progression. A recent report by Marrogi et al (1999) described a high frequency of p53 mutations in tumoral MF samples, but this has not been confirmed in other series (Garatti et al, 1995) .
Concerning the role of the 9p21 locus, Peris et al (1999) have shown a lack of p16
INK4a protein expression in patients with MF, suggesting that alterations in this gene might play a pathogenic role in this type of cutaneous lymphoma. Moreover, a previous report by our group (Navas et al, 2000) showed that alterations of p16
INK4a are frequent in MF cases with aggressive transformation, but we were unable to determine whether p16
INK4a silencing is a frequent and early finding in all cases of MF or only in the subset of cases showing progression. In the first instance, p16
INK4a alterations could be a characteristic finding of the disease, whereas in the second, p16
INK4a silencing would be a risk factor for disease progression. On the other hand, information about p14 ARF and p15
INK4b status in MF is scarce. The aim of this study was to investigate the hypothetical pathogenic role of p16
INK4a , p15 INK4b , and p14 ARF inactivation in a group of stable MF patients (patch/plaque lesions that had not progressed after a minimum of 30 months of follow-up), comparing them with aggressive MF before and after progression.
Results

Clinical Data
The clinical data of the patients with stable and aggressive MF are summarized in Table 1 .
There were 11 patients with aggressive MF. All of them developed tumoral lesions mostly evidenced by In four patients the patch/plaque and tumoral samples were taken simultaneously. In five patients, patch/plaque samples were taken 10 to 94 months before sampling of tumoral lesions. In two of them, samples of tumoral lesions were taken 7 and 24 months before the plaque lesion. Patient MF90 died of lymphoma. Patient MF122 died of a pulmonary small cell cancer. The rest of the patients are still alive. Three of the patients (MF36, MF82, and MF79) achieved complete remission (CR), and they remain free of disease after 41, 101, and 16 months of follow-up, respectively. Only three remaining patients (MF73, MF78, and MF91) underwent CR during their medical history, at 6, 11, and 8 months, respectively.
Molecular Studies
A (Table 2) .
In patients with stable MF, alterations of the p16
INK4a gene were detected in 7 (18%) of 39 and alterations of the p15
INK4b gene were detected in 2 (5%) of 39 of the lesions. None of the 39 cases analyzed showed alterations of the p14 ARF gene. Only methylation of some of these genes was observed, and no genetic loss was detected.
In contrast with these results, in patients with aggressive MF (11 cases), alterations of the p16 INK4a gene were found in 8 (73%) of 11 tumoral samples (2 cases of allelic loss [MF36, MF113] and 6 of methylation); alterations of the p15
INK4b gene were found in 3 (27%) of 11 samples (2 cases of allelic loss [MF36, MF113] and 1 of methylation); and alterations of the p14 ARF gene were found in 2 (18%) of 11 samples (2 cases of allelic loss [MF36 and MF113] ). All of these alterations were present in the tumoral phase. When analyzing the plaque stage of these aggressive MF, alterations of the p16
INK4a gene were found in 4 (36%) of 11 samples (1 allelic loss and 3 methylation); alterations of the p15
INK4b gene were found in 2 (20%) of 10 samples (1 case of allelic loss and 1 of methylation); and alterations of the p14 ARF gene were found in 1 (10%) of 10 samples (1 allelic loss) (Table 3) .
Allelic Loss Studies
In 21 cases of patients with stable MF, DNA was available from nontumoral tissue for the analysis of microsatellites surrounding the p16 INK4a , p15  INK4b ,  and p14 ARF genes in the 9p21 region. None of the 21 cases analyzed showed allelic loss.
In contrast with this finding, in patients with aggressive MF, 3 of 11 samples taken in the tumoral phase showed genetic loss, 1 showed HD, and 2 showed LOH. In one of these cases (MF39), LOH was detected in only two contiguous markers, without including the p16 INK4a , p15 INK4b , and p14 ARF genes. Some of these data have been previously published (Navas et al, 2000) ( Fig. 1; Table 3 ).
Aberrant Methylation at the 5'-CpG Islands in 9p21 Gene Cluster
The methylation status of the p16
INK4a , p15 INK4b , and p14 ARF CpG islands was investigated in 58 MF samples (Fig. 2) .
Methylation of the p16 INK4a gene was found in only 7 (18%) of 39 lesions from cases of stable MF, whereas it was observed in 6 (60%) of 10 tumoral samples from cases of aggressive MF. When analyzed, plaque lesions of aggressive forms of MF showed an intermediate value, and 3 (33%) of 9 of cases were positive. Some of these data have been previously published (Navas et al, 2000) .
Methylation of the p15 INK4b gene was found in 2 (5%) of 39 cases of stable MF. In aggressive MF, p15
INK4b hypermethylation was observed in 2 (20%) of 10 cases, associated in both with p16 methylation. No case showed p14 ARF gene methylation (Table 3 ). All of the 35 negative controls included (skin, lymphoid tissue in different reactive conditions, and peripheral blood lymphocytes) showed amplification with unmethylated-specific primers (U) but not with methylated-specific primers (M).
Mutational Analysis
To determine whether mutations of the p16
INK4a and p53 gene were present, exons 1 and 2 and 5 to 8 of these genes, respectively, were analyzed by direct sequencing. None of the nine cases studied, all of which corresponded to tumoral lesions, showed mutations in any of the genes.
Immunohistochemical Studies
Immunohistochemical studies for p16
INK4a were performed on paraffin-embedded tissue samples from 39 Table 4 , and lacking molecular alterations (2/5 cases showed a mixture of positive and negative cells). In 27 cases, intraepithelial and atypical lymphocytes showed a nuclear distinct expression, comparable to that seen in the epithelial cells. Representative cases are illustrated in Figure 3 .
Correlation Between Clinical and Molecular Data
We statistically compared the 39 patients with stable MF and the 11 patients with aggressive MF (Wilcoxon and median score tests). We could find no significant differences between the two populations in terms of 
3/9 6/10 1/7 1/9 0/7 0/9 1/9 3/11 0/9 HD, homozygous deletion; LOH, loss of heterozygosity; ND, not done; ϩ, positive; Ϫ, negative. a The results corresponding to the p16 INK4a gene of these patients have been published previously (including deletion, mutation, and methylation analysis) (Navas et al, 2000) .
b wt due to reactive cells associated with the tumor as it presents HD. c In case MF39, LOH was detected in two markers, without including p16 INK4a , p15 INK4b , and p14 ARF genes (Navas et al, 2000) .
Figure 1.
Summary of microsatellite analysis of locus 9p21 in aggressive mycosis fungoides (MF). Three samples that showed deletions at one or more loci are presented. All of them are illustrated in plaque (PL) and tumoral (T) stages. The status of each chromosomal locus is indicated as follows: Ⅵ, homozygous deletion; u, loss of heterozygosity; , retention of both alleles; □, noninformative;^, noninformative loci with a signal markedly diminished in comparison with DNA normal. Navas et al sex distribution, age at onset, the mean time interval between the first clinical manifestation of MF and the date of the biopsy, time of follow-up after the biopsy specimen was analyzed, or treatments performed before the biopsy specimen was analyzed. Both populations were homogeneous.
We then analyzed the frequency of inactivation of the different genes, when comparing stable and aggressive forms of MF. When we investigated p16 INK4a inactivation (secondary to both genetic loss and/or hypermethylation), we found that the frequency of p16
INK4a inactivation was significantly higher in tumoral lesions corresponding to aggressive MF (8/11, 73%). In comparison with this, in the biopsy specimens taken from the stable form of MF, p16
INK4a inactivation was present in 7 (18%) of 39 cases. The comparison between the tumoral lesions of aggressive MF and the stable MF yielded statistically significant differences (p ϭ 0.001, Fisher's exact test). This difference was also present when only hypermethylation was analyzed (6/10 vs. 7/38; 60% vs. 18%) (p ϭ 0.01, Fisher's exact test).
Plaque lesions of those patients who developed an aggressive form of MF also showed more frequent p16
INK4a inactivation (4 [36%] of 11 cases) than stable plaque lesions (7 [18%] of 39 cases). This was not statistically significant.
Status of Stable MF with 9p21 Alterations
There were no statistical differences in the epidemiologic data of the patients with stable MF, whether p16 INK4a was hypermethylated or not. Two patients presented p15 INK4b hypermethylation. One patient then was under RePUVA treatment when she underwent biopsy, whereas the other was not receiving any treatment. They remain alive in the IIa and Ia stages, respectively.
Seven patients presented p16 INK4a hypermethylation. Three of them are in Stage Ia, one is in Stage Ib, and three are in complete remission. One patient had associated lymphomatoid papulosis. Three patients were receiving topical corticosteroids when they underwent biopsy. The rest were not being treated.
Discussion
MF is a cutaneous T-cell lymphoma whose clinical and morphologic characteristics have been thoroughly described. However, despite the high frequency of aggressive transformation in this disease, knowledge of the molecular mechanisms involved in pathogenesis of the tumoral progression is still scarce. The 9p21 locus seems to be a good target for a detailed study in MF, because some previous studies on cutaneous T-cell lymphoma have already pointed out some of the genes present in this chromosomal region. Thus deletions in this area have been characterized by Ogawa et al (1995) and Stranks et al (1995) in two cases of Sézary syndrome; Peris et al (1999) showed a reduced expression of p16
INK4a in MF lesions, and our own group (Navas et al, 2000) has shown a relatively high frequency of p16
INK4a inactivation when only aggressive forms of MF were analyzed. Nevertheless, so far no study has compared the frequency of inactivation of the different genes codified in 9p21 between aggressive versus quiescent forms of cutaneous T-cell lymphoma, which could eventually point out key targets for the prediction of progression and therapeutic intervention.
This study had the aim of supplying this information, by comparing the status of p16
INK4a , p15 INK4b , and p14 ARF genes in a large series of aggressive MF with a group of 39 cases of stable MF, as defined by the absence of progression in a minimum follow-up of 30 months.
Alterations in the p16 INK4a gene were clearly more frequent than in the p15
INK4b and p14 ARF genes.
Inactivation of the p16
INK4a gene (hypermethylation or deletion) was found in 18% (7/39) of the lesions of stable MF versus 73% (8/11) of the tumoral lesions of aggressive MF. Statistical analysis was able to detect significant differences when comparing plaque lesions of stable MF with tumoral lesions of aggressive MF (p ϭ 0.001, Fisher's exact test). This finding is parallel with those obtained in B-cell lymphomas, where silencing of p16
INK4a has been found to play a critical role in tumoral progression (Elenitoba-Johnson et al, 1998; Pinyol et al, 1998; Villuendas et al, 1998) .
The frequency of p16 INK4a alterations in the plaque lesions of those cases that go on to show tumoral transformation (36%) was also higher than in the plaque lesions of stable MF (18%), although these differences did not attain statistical significance. Similarly, the frequency of p16
INK4a alterations was higher in tumoral lesions (73%) than it was in plaque lesions of aggressive MF (36%), but these differences were not significantly different either. The relatively small size of our series can make proportions that practically double each other statistically insignificant. These data are compatible with the hypothesis that p16
INK4a inactivation could be a necessary step for tumoral progression of MF, but additional changes are required to allow or accelerate the progression, because as shown, not all cases with p16
INK4a inactivation necessarily progress to aggressive forms during the length of this study.
We have also taken into account the possibility that the lower frequency of p16
INK4a alterations in plaque lesions may only reflect a smaller population of tumoral cells within lesions of this kind. We therefore performed sensitivity assays that showed that the methylation-specific PCR (MSP) technique used was able to detect methylation when the amount of tumoral cells was 0.5% for p16
INK4A , 10% for p15 INK4b , and 2.5% for p14 ARF (data not shown). The samples analyzed here included the necessary amount of tumoral cells, as assessed by morphologic and immunohistochemical staining. Thereafter, the use of immunohistochemical staining for p16
INK4A has made it possible to confirm the results obtained by LOH and MSP, with only a minor exception, two cases with a mixture of p16
INK4A -positive and -negative cells. Additionally, the percentage of tumoral cells in plaque stage MF was previously found to exceed the threshold of sensitivity of a PCR technique for detection of TCR-␥ rearrangements, located in 10% of tumoral cells (Algara et al, 1994) .
A relatively low frequency of changes involving p15
INK4B genes were observed in this study, and additionally in aggressive MF no case was observed to harbor changes exclusively in the p15
INK4b gene, because all cases showed concomitant alteration of the p16
INK4a gene. Thus alterations of the p15 INK4b gene (deletion and methylation) were observed in 2 (5%) of 39 patients with stable MF and in 3 (27%) of 11 of tumoral samples. Consistent with these results, and in concordance with previous observations in which HDs at 9p21 generally occur at a low frequency in non-Hodgkin's lymphomas (Drexler, 1998; Gombart et al, 1995; Koduru et al, 1995; Ogawa et al, 1995; Siebert et al, 1995; Uchida et al, 1995) , only one case in this series (MF36) showed HD in the p16 INK4a , p15 INK4b , and p14 ARF genes. It seems that at least in this tumoral model, the concurrent inactivation of the p16
INK4a and p15
INK4b genes just gives a relatively small additional advantage on tumoral cells, thus confirming the diversity of situations observed in lymphomas when analyzing the 9p21 genes (Baur et al, 1999; Drexler, 1998; Elenitoba-Johnson et al, 1998; Pinyol et al, 1998; Villuendas et al, 1998) . It is, nevertheless, noteworthy that the two cases with double inactivation of both p16/Rb and ARF/p53 pathways showed an aggressive form of the disease, as could be predicted.
Generally speaking, these results seem to support that tumoral progression in MF is associated with a very high frequency of p16/Rb pathway silencing and preservation of the ARF/p53 pathway, as is shown by the rarity of p53 mutation or p14 ARF silencing. Strikingly, p53 alterations were not observed in any case in this series, which contrasts with data published previously by Marrogi et al (1999) . No explanation is suggested for this difference, because all cases in our series were sequenced from exon 5 to 8, the same area where p53 mutations were observed in the study by Marrogi et al (1999) .
The tumoral progression of MF may be related to alternative additional mechanisms. Cytokines are believed to play an important role in the pathogenesis of cutaneous T-cell lymphoma (Rook et al, 1997) . MF progression has been associated with significantly higher IL-10 and lower IFN-␥ mRNA expression (Asadullah et al, 1996) suppressing normal T-cell activity and giving the malignant T cells a growth advantage. Several mechanisms may therefore contribute to tumor progression, and the likelihood of a single factor being solely responsible is probably low.
Unfortunately, the results of this study do not make it possible to conclusively predict whether a de novo patient with MF will show an accelerated phase, using only examination of p16
INK4a status. However, because the hypermethylation of the p16
INK4a promoter was the preferred mechanism of inactivation of the p16
INK4a gene in our patients, it suggests that efforts aimed at reversing the methylation status of p16
INK4a
could have a positive impact on the evolution of the disease. In the future, demethylating agents-such as decitabine, or others-could be used to design clinical assays in this group of patients (Wijermans et al, 2000) .
Material and Methods
Case Selection
A group of patients with MF was selected from the medical records of the 12 de Octubre Hospital, Madrid, and the Virgen de la Salud Hospital, Toledo (both of which are in the center of Spain). Diagnosis was based on generally accepted clinicopathologic criteria. Patch or plaque lesions were erythematous, slightly scaling macules or plaque lesions with welldefined borders. Histopathologically they presented a characteristic infiltrate of epidermotropic atypical T cells with convoluted cerebriform nuclear contours. Tumors were defined as nodules, whether or not they were ulcerated, with a majority of large cells on histopathologic examination.
We defined "stable MF" as cases that had not progressed into tumoral stages in at least 30 months Navas et al of follow-up after the biopsy. We could obtain freshfrozen material from 39 stable MF cases with patches/ plaques (13 T1, 26 T2). Until January 2001 the minimum follow-up without progression into tumoral stage was 34 months. "Aggressive MF" was defined as cases that progressed into tumoral stage. We identified 11 MF cases from which we could obtain formalin-fixed paraffin-embedded tissue or freshfrozen material from patch/plaque as well as tumoral lesions. Some patients had patch/plaque and tumoral lesions present simultaneously on different areas on their skin. Some of the findings concerning nine of these cases have been published previously (Navas et al, 2000) . All of the samples analyzed were studied in parallel for routine hematoxylin-eosin examination.
Complete remission is defined as no evidence of residual disease after a follow-up of at least 3 months. The TNM staging system was used, as defined by the MF Co-operative Group of Mycosis Fungoides/Sézary Syndrome.
